Cancer care increasingly depends on understanding how genetic changes drive tumor progression. Genomic insights help guide therapy choices, inform clinical trial enrolment, and drive the development of new treatments. For clinicians and researchers, the challenge is keeping pace with rapidly advancing knowledge bases while ensuring results translate into meaningful options for patients.
The pace of oncology research means knowledge about variants that drive cancer and therapeutic options changes constantly. Linking genetic findings to available treatments, trial opportunities, and emerging biomarkers is complex. Meanwhile, clinicians and researchers face pressure to deliver results quickly and with confidence, knowing that decisions directly affect patient care and treatment outcomes.
Saphetor supports oncology teams in translating tumour sequencing data into clinically meaningful insights. By combining trusted variant calling, curated knowledge sources, guideline-driven classification, and AI-assisted variant prioritization, VarSome helps clinicians and researchers connect variants to therapies, biomarkers, and clinical trials with confidence. Integrated resources such as OncoKB™ and our Somatic Classifier keep interpretations aligned with current evidence, while assay flexibility and deployment options allow institutions to adapt analysis to existing workflows.
